ExpertiseUpdated on 28 May 2026
Entry portal through the intestinal barrier
Business Development Manager at Ghent University - provaxs
Merelbeke, Belgium
About
Controlled transfer of biological compounds through the intestinal (mucosal) barrier via targeting of the compound to a defined receptor (APN) on the epithelium.
Via selective transcytosis through the intestinal barrier various functions at the level of the intestinal epithelium and beyond can be modulated: i) antigens can be efficiently presented to the gut associated lymphoid tissue (GALT) leading to a protective mucosal immune response and ii) drugs or drug-containing (nano-)particles can be transferred and delivered across the intestinal barrier.
Field
- Vaccine Development
- Immunology
- Immunotherapy
- Infectious Diseases
Organisation
Similar opportunities
Expertise
Blood-Brain Barrier in vitro to in vivo models
An Voets
business developer BIOMED / academic liaison manager Health Campus Limburg DC at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium
Expertise
Controlled expression of sa-mRNA
- Immunology
- Immunotherapy
- Clinical Trials
- Preclinical trials
- Vaccine Development
Sven ARNOUTS
Business Development Manager at Ghent University - provaxs
Merelbeke, Belgium
Expertise
Angiogenesis in vitro to in vivo toolbox
An Voets
business developer BIOMED / academic liaison manager Health Campus Limburg DC at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium